View in EDS

Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.

Saved in:
Bibliographic Details
Title: Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.
Authors: Zhu X; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Alvarez EA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Umetsu SE; Department of Pathology, University of California, San Francisco, San Francisco, California., Chapman JS; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Chen LM; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Ueda S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California., Henderson S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Nguyen P; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Calabrese S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Russell J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Aguilar J; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Smith SA; AstraZeneca (United Kingdom) , Cambridge, United Kingdom., Shah N; AstraZeneca (United Kingdom) , Cambridge, United Kingdom., Feeney L; AstraZeneca (United Kingdom) , Cambridge, United Kingdom., Van Ziffle J; Genomic Medicine Laboratory, University of California, San Francisco, San Francisco, California.; Institute for Human Genetics, University of California, San Francisco, San Francisco, California., Turski ML; Molecular Oncology Initiative, University of California, San Francisco, San Francisco, California., Ko AH; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Munster PN; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Ashworth A; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Collisson EA; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Aggarwal RR; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 01; Vol. 32 (9), pp. 1632-1640.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41686845
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhu+X%22">Zhu X</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Alvarez+EA%22">Alvarez EA</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Umetsu+SE%22">Umetsu SE</searchLink>; Department of Pathology, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Chapman+JS%22">Chapman JS</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Chen+LM%22">Chen LM</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Ueda+S%22">Ueda S</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology & Reproductive Sciences, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Henderson+S%22">Henderson S</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Nguyen+P%22">Nguyen P</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Calabrese+S%22">Calabrese S</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Russell+J%22">Russell J</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Aguilar+J%22">Aguilar J</searchLink>; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Smith+SA%22">Smith SA</searchLink>; AstraZeneca (United Kingdom) , Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Shah+N%22">Shah N</searchLink>; AstraZeneca (United Kingdom) , Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Feeney+L%22">Feeney L</searchLink>; AstraZeneca (United Kingdom) , Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Van+Ziffle+J%22">Van Ziffle J</searchLink>; Genomic Medicine Laboratory, University of California, San Francisco, San Francisco, California.; Institute for Human Genetics, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Turski+ML%22">Turski ML</searchLink>; Molecular Oncology Initiative, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Ko+AH%22">Ko AH</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Munster+PN%22">Munster PN</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Ashworth+A%22">Ashworth A</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Collisson+EA%22">Collisson EA</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Aggarwal+RR%22">Aggarwal RR</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2026 May 01; Vol. 32 (9), pp. 1632-1640.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41686845
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-25-4043
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1632
    Titles:
      – TitleFull: Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhu X
      – PersonEntity:
          Name:
            NameFull: Alvarez EA
      – PersonEntity:
          Name:
            NameFull: Umetsu SE
      – PersonEntity:
          Name:
            NameFull: Chapman JS
      – PersonEntity:
          Name:
            NameFull: Chen LM
      – PersonEntity:
          Name:
            NameFull: Ueda S
      – PersonEntity:
          Name:
            NameFull: Henderson S
      – PersonEntity:
          Name:
            NameFull: Nguyen P
      – PersonEntity:
          Name:
            NameFull: Calabrese S
      – PersonEntity:
          Name:
            NameFull: Russell J
      – PersonEntity:
          Name:
            NameFull: Aguilar J
      – PersonEntity:
          Name:
            NameFull: Smith SA
      – PersonEntity:
          Name:
            NameFull: Shah N
      – PersonEntity:
          Name:
            NameFull: Feeney L
      – PersonEntity:
          Name:
            NameFull: Van Ziffle J
      – PersonEntity:
          Name:
            NameFull: Turski ML
      – PersonEntity:
          Name:
            NameFull: Ko AH
      – PersonEntity:
          Name:
            NameFull: Munster PN
      – PersonEntity:
          Name:
            NameFull: Ashworth A
      – PersonEntity:
          Name:
            NameFull: Collisson EA
      – PersonEntity:
          Name:
            NameFull: Aggarwal RR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 32
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1